Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seres Therapeutics Inc
(NQ:
MCRB
)
1.150
+0.080 (+7.48%)
Streaming Delayed Price
Updated: 11:51 AM EDT, Jun 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seres Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Preview: Seres Therapeutics's Earnings
May 08, 2023
Via
Benzinga
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
May 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
May 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Where Seres Therapeutics Stands With Analysts
April 28, 2023
Via
Benzinga
Why Seres Therapeutics Shares Are Surging Thursday Morning
April 27, 2023
Via
Benzinga
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
April 20, 2023
These two biotech stocks might be significantly undervalued.
Via
The Motley Fool
Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday
April 28, 2023
Wells Fargo raised the price target for Molina Healthcare, Inc. (NYSE: MOH) from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8%...
Via
Benzinga
Snap, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
April 28, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
April 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Where Seres Therapeutics Stands With Analysts
March 08, 2023
Via
Benzinga
Seres Therapeutics Earnings Preview
March 06, 2023
Via
Benzinga
Tesla, Meta Platforms, Seres Therapeutics, Atomera, Roku: Why These 5 Stocks Are Drawing Investors' Attention Today
April 26, 2023
Via
Benzinga
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
April 26, 2023
From
Seres Therapeutics, Inc. and Nestlé Health Science
Via
Business Wire
Amazon, Microsoft, Alphabet And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
April 26, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
April 21, 2023
Via
Benzinga
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
April 04, 2023
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
Via
The Motley Fool
Stocks React To February Jobs Report: The Winners And Losers
March 10, 2023
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors.
Via
Benzinga
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
February 28, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
February 14, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
February 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
January 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.